Citius Pharma (CTXR) Provides Current Information on its Pipeline and Indicates Potential Near-Term Catalysts

Citius Pharma (CTXR) Provides Current Information on its Pipeline and Indicates Potential Near-Term Catalysts

Good day everyone,

WE are updating our coverage of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products.

Current price $1.97 per share
Outstanding shares (est.) 134.7M
Float (est.) 68.1M

The last time we reported on CTXR was December of last year and a lot has happened since then. Back in December, the company’s Mino-Lok product was in a Phase III trial, Mino-Wrap and Hydro Lido were in early clinical development, and their i-MSC therapy, licensed from Novellus was in the proof-of-concept stage.

Four products in development
Late-stage Phase III trial
Catalysts already lined up for 2021.
Trending shares
More than $4 billion in potential markets
Shares trading 32% off their February high

As indicated in the company stock chart, 2021 has been a good year for the company shares thus far. Starting the year at $1.02/share, they peaked at $2.90 on February 22nd before consolidating to today’s level. That’s an 86% gain year to date.

When CTXR shares climbed to $2.90 in February, we thought the shares were finally moving toward a better reflection of the company’s potential value, even though $2.90 is less than half the current analysts price target (see below). When the share price stayed consistently under $2.00, we saw value.

A rapid gain in market value can also release the sharks (short interest traders) and that has happened at CTXR. Short interest on April 29th was approx. 13.8M shares (19.2% of the float), a significant position. There appears to be an opportunity for some level of short squeeze here. Together we are strong.

Evaluating a market value for pre-profit biopharma companies can be difficult, but we can look at the viability of the product pipeline and the size of the potential markets to get an idea. Biopharma companies looking for an acquisition utilize this method. We discuss both criteria for CTXR below.

CTXR has a current market value of $258M, a level we believe may be too low given the viability of the pipeline and a potential to penetrate $4 billion in markets.

Citius is advancing four product candidates: 1) Mino-Lok® is in Phase III trials and is enrolling patients, 2) Halo-Lido (CITI-002) is being prepared for a Phase IIb trial, and 3) Mino-Wrap™ (CITI-101) is in pre-clinical stage, 4) Novecite (CITI-004) is in the pre-clinical stage. The markets for these products are large, underserved, and provide unique opportunities for the company. Mino-Lok and Mino-Wrap are the results of licenses with MD Anderson Cancer Center. NoveCite is licensed from Novellus, Inc. Halo Lido is a CTXR product.

Founders and company officers have cumulatively invested $26.5 million into the Company. CEO Myron Holubiak participated in a video interview this week to discuss the company’s progress and direction for 2021. Mr. Holubiak provides up to date information and background on the company in this video.

The market potential for an effective antibiotic lock therapy (Mino-Lok) is estimated at $750 million per year in the U.S. and is projected to reach $1.84 billion globally.

The market opportunity for preventing post-mastectomy infections (Mino-Wrap) in the U.S. is estimated at $400 million per year.

The worldwide market for prescription strength hemorrhoid treatment (Halo Lido) is $2 billion.

The market for a treatment for Acute Respiratory Distress Syndrome (Novecite) has not been determined but may be in the $billions.

CTXR is transparent about its product development and has offered these potential catalyst events for this year and beyond:

Mino-Lok IND Filing Q4 ‘21
Halo Lido IND Filing Q3 ‘21
Halo Lido Phase IIb Trial Start Q3 ‘21
Mino-Lok Phase III Interim Efficacy Q2 ‘21
Mino-Lok Phase III Trial Completed Q3 ‘21
NoveCite IND Filing Q1-2 ‘22
Mino-Lok NDA Submission Q4 ‘21

Analysts seem to indicate unrealized value in the company shares.
3/1/2021 HC Wainwright Buy
2/25/2021 Dawson James Buy $6.00

Stay tuned for our full report on CTXR coming soon where we will discuss the company pipeline in further detail.

Together we’re strong,
The Traders News Group


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website have been compensated twenty one thousand dollars cash via bank wire for our distributed opinions this week on ctxr. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.